During the prospective follow-up of 64 babies at risk for perinatal HIV-1 infection because their mothers were, seropositive, and of 130 control babies whose mothers were seronegative, we studied the occurrence of complications of bacillus Calmette-Cuérin (BCC) immunization and its ability to induce cutaneous reactivity to tuberculin. Babies born both to HIV-I-positive and HIV-I-negative mothers received BCC immunization during their first month of life according to the Expanded Programme on Immunization (EPI) recommendations. Local and regional complications of BCG vaccine were looked for at 3,6 and 9 months after inoculation. A tuberculin skin test was performed at 6 or 9 months of age. Most babies born to HIV-I-positive mothers were later classified as infected or uninfected according to their clinical condition and/or serological status at 18 months of age. The mean duration of the follow-up was . 36 months (range 30-40 months). No chronic or deep ulcerations at the site of injection or disseminated forms of BCC infection were observed. The frequency of BCC-related lymphadenitis in the group of HIV-I-infected children (24%) did not differ significantly from the group of uninfected children (19%; Fisher test: P = 0.73). In cohtrast, the tuberculin skin test responses were positive less often in the group of HIV-I-infected children (33%) than in the uninfected group (83%; Fisher test: P = 0.007). Because BCC vaccine appears to be safe -even when given to perinatally infected babies -continuation of the BCC immunization policies of the EPI is justified, especially in view of the growing incidence of tuberculosis as a complication of HIV infection.
Introduction

I
Tuberculosis is of major public health importance in Africa and is becoming an even greater problem because of its exacerbation by the HN epidemic [1, 2] . In areas were tuberculosis is endemic, bacillus Calmette-Guérin (BCG) immunization at birth is still the basic method for tuberculosis prevention [ 3-51. Fatal complications of BCG immunization have been reported in infants with congenital immunodeficiency [ 6, 7] , and case reports have raised doubts about the safety of BCG in HIV: 1- infected infants because of their impaired immunity [t3-13]. In addition, the presence of HIV-related immunodeficiency might decrease the response to tuberculin antigen and the accompanying protective effect of BCG immunization [ 1 4 3 J.
To date, no published study in infants has given prospective data concerning the effect of BCG inlmunization in the setting of HIV infection. The present investigation was designed within an established prospective cohort study on mother-child transmission of HIV infection [ 16 J. The objective of our investigation was to evaluate both the occurrence of locoregional complications of BCG inoculation at birth, and the induction of subsequent tuberculin reactivity in HIV:l-infected and uninfected infants bom to seropositive mothers and in control infants bom to seronegative mothers.
Subjects and methods
Pregnant women were recruited sequentially, after giving informed consent, during their first prenatal visit to one of two mother-child clinics serving the eastern districts of Brazzaville, Congo. Sera were tested for antibodies to HN-1 by enzyme-linked immunosorbent assay (EUS4 ELAVIA, Diagnostics Pasteur, Marnes-La-Coquette, France). Positive ELISA tests were confirmed by Westem blot (Blot test, Du Pont de Nemours, W W gton, Delaware, USA). Sera were considered positive when they showed antibodies to at least two envelope &CO-proteins of HIV-1.
Each seropositive woman was individu@ matched for age, estimated date of delivery, and place of residence (district) with two seronegative pregnant women. Mer birth, infants were followed with clinical examination and blood sampling by the same physician at 1 month, 3 months, and every 3 months thereafter (active followup included home visit for individuals not presenting for scheduled visits). The mean duration of the follow-up was 36 months (range 30-40 months).
Babies bom to both seropositive and negative mothers received BCG immunization (Pasteur Vacdns, strain 1173P2, Diagnostics Pasteur) during their first month of life according to the World Health Organization (WHO) recommendations: 0.05 mg in 0.05 ml via intradermal injection on the lateral surface of the left arm [171.
The infants were examined for local and regionat complications of BCG immunization at 3, 6 and 9 months after inoculation. holated left arrillary and/or supraclavicular lymph nodes >Icm in diameter, without other discernible local cause, were considered to be related to
BCG.
A tuberculin skin test (Monotest, Mérieux, Lyon, France; intradermal route by multipuncture of tuberculin antigen at a dose of 300 O00 IU/ml) was performed at 6 or 9 months of age. The delayed hypersensitivity response to tuberculin was reported by the same physician 48 h later. A positive skin reaction was delined as an area of induration with a diameter > 2 mm [l8] .
The 178 babies on whom follow-up studies are available were subdivided into four groups. Group 1: HIV- 
Results
F~fty-two of the 64 infants bom to seropositive mothers (81%) and 127 out of 130 infants bom to seronegative mothers (98%) were vaccinated by BCG and could be traced for more than 3 months. The other babies were either lost to follow-up (one bom to a seropositive mother and one to a seronegative) or had died (11 had sero9si-tive and two had seronegative mothers). Causes of death are shown in Table 1 . 
Discussion
The results from this study show that there was no significant difference in the frequency of BCG-related lynphadenopathy either in babies bom to HIV- In the present study, the fact that HW-1 infection in infants was associated with a lower frequency of positive tuberculin tests suggests the early occurrence of immunodeficiency in infected infants. The percentage of negative tuberculin tests among infants might have been underestimated, since seved of these infants died of conditions related to HIV-1 immunodeficiency before they were skin-tested, and they most likely would have scored as tuberculin-negative. Nevertheless, 33% of the HIV-1-infected infants in whom the response to tuberculin was evaluated did develop a positive test and, therefore, might have achieved a level of protection against serious complications of primary tuberculosis [29, 30] .
In HIV-endemic areas in which BCG immunization is utilized, the HIV-1 serostatus of a mother may be known. In this setting, given the particularly high risk of tuberculosis for infants (HIV-1-infected or uninfected) and the likelihood of an HIV-seropositive mother having tuberculosis, BCG immunization can be safely performed except in symptomatic infànts. The feasibility of routine HN-1 screening in pregnant women is low virtually everywhere in Africa [31] , and the diagnosis of HIV-1 infection in neonates is not practical [32] . Therefore, immunization strategies can be planned only at a population level. From the results of the present study, we conclude that the EPI policies on BCG immunization [33] should be reinforced in areas where J3V-l infection is highly prevalent because (1) BCG immunization is safe, irrespective of the serological status of mothers and infants; (2) the risk of tuberculosis is greatly increased in regions such as subSaharan Africa where there is a high prevalence of both tuberculosis and HIV infection [34] [35] [36] [37] [38] ; (3) the protection conferred by BCG immunization to uninfected babies bom to seropositive mothers far outweighs the theoretical risk of disseminated infection in HIV-infected babies, and (4) some HIV-infected children (those who develop a positive tuberculin skin test) may be transiently protected from serious complications of primary .tuberculosis.
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